|
End-of-day quote
EURONEXT - EURONEXT LONDON
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| 10-05 | Swiss Market Index Begins Week in Green; Nestlé Shares Edge Down | MT |
| 10-05 | BofA Expects Higher Q3 Sales from Novartis Amid Strong Key Growth Drivers | MT |
Company Valuation: Novartis AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 196,458 | 194,448 | 207,167 | 195,514 | 266,003 | 268,112 | - | - |
| Change | - | -1.02% | 6.54% | -5.62% | 36.05% | 0.79% | - | - |
| Enterprise Value (EV) 1 | 204,649 | 203,482 | 219,178 | 213,458 | 289,870 | 299,604 | 296,402 | 289,731 |
| Change | - | -0.57% | 7.71% | -2.61% | 35.8% | 3.36% | -1.07% | -2.25% |
| P/E | 8.2x | 28.3x | 14.1x | 16.5x | 19.2x | 19.9x | 16.7x | 14.5x |
| PBR | 2.9x | 3.23x | 4.41x | 4.52x | 5.73x | 5.66x | 5.3x | 4.91x |
| PEG | - | -0.4x | 0x | -1x | 0.9x | -12.99x | 0.9x | 1x |
| Capitalization / Revenue | 3.81x | 3.85x | 4.44x | 3.78x | 4.69x | 4.65x | 4.37x | 4.11x |
| EV / Revenue | 3.96x | 4.03x | 4.7x | 4.13x | 5.11x | 5.19x | 4.83x | 4.44x |
| EV / EBITDA | 11.2x | 10.9x | 12.2x | 10.2x | 12.4x | 12.8x | 11.7x | 10.6x |
| EV / EBIT | 12.3x | 12.2x | 13.4x | 10.9x | 13.2x | 13.7x | 12.5x | 11.3x |
| EV / FCF | 15.4x | 17x | 16.6x | 13.1x | 16.5x | 19.3x | 17.5x | 15.2x |
| FCF Yield | 6.49% | 5.87% | 6.01% | 7.61% | 6.07% | 5.19% | 5.71% | 6.6% |
| Dividend per Share 2 | 3.36 | 3.5 | 3.823 | 3.856 | 4.762 | 4.336 | 4.522 | 4.756 |
| Rate of return | 3.83% | 3.87% | 3.79% | 3.94% | 3.44% | 3.07% | 3.21% | 3.37% |
| EPS 2 | 10.71 | 3.19 | 7.15 | 5.92 | 7.21 | 7.1 | 8.445 | 9.729 |
| Distribution rate | 31.4% | 110% | 53.5% | 65.1% | 66% | 61.1% | 53.5% | 48.9% |
| Net sales 1 | 51,626 | 50,545 | 46,660 | 51,722 | 56,674 | 57,691 | 61,392 | 65,267 |
| EBITDA 1 | 18,246 | 18,613 | 17,937 | 21,006 | 23,415 | 23,338 | 25,271 | 27,205 |
| EBIT 1 | 16,588 | 16,665 | 16,372 | 19,494 | 21,889 | 21,802 | 23,642 | 25,592 |
| Net income 1 | 24,021 | 6,955 | 14,854 | 11,939 | 13,967 | 14,474 | 16,096 | 17,924 |
| Net Debt 1 | 8,191 | 9,034 | 12,011 | 17,944 | 23,867 | 31,492 | 28,290 | 21,620 |
| Reference price 2 | 87.82 | 90.40 | 100.79 | 97.79 | 138.63 | 141.06 | 141.06 | 141.06 |
| Nbr of stocks (in thousands) | 2,237,092 | 2,150,980 | 2,055,460 | 1,999,270 | 1,918,792 | 1,900,715 | - | - |
| Announcement Date | 2/2/22 | 2/1/23 | 1/31/24 | 1/31/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.46x | 11.79x | 23.8x | 0.61% | 1,019B | |
| 28.13x | 6.24x | 17.86x | 2.11% | 610B | |
| 33.64x | 7.86x | 16.24x | 2.61% | 470B | |
| 101.52x | 5.7x | 24.22x | 2.45% | 344B | |
| 18.95x | 4.61x | 11.45x | 2.87% | 336B | |
| 19.74x | 5.16x | 12.75x | 3.1% | 266B | |
| 19.84x | 4.13x | 11.77x | 2.15% | 241B | |
| 25.45x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.74x | 6.39x | 24.95x | 2.28% | 179B | |
| Average | 26.22x | 6.50x | 17.21x | 2.3% | 409.2B | |
| Weighted average by Cap. | 31.25x | 7.60x | 18.53x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NOVN Stock
- Stock
- Valuation Novartis AG
Select your edition
All financial news and data tailored to specific country editions
